Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression.
Context.-- Human epidermal growth factor receptor 2 (HER2) status in breast cancer is currently classified as negative or positive for selecting patients for anti-HER2 targeted therapy. The evolution of the HER2 status has included a new HER2-low category defined as an HER2 immunohistochemistry scor...
| Publicado en: | Archives of Pathology & Laboratory Medicine Vol. 148; no. 2; pp. 242 - 256 |
|---|---|
| Autores principales: | , , , , , , , , , |
| Formato: | pictorial review tables/charts Journal Article |
| Publicado: |
College of American Pathologists
Feb2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=175180329&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 175180329 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00039985 1FS jtl: Archives of Pathology & Laboratory Medicine issn: 00039985 maglogo: N pubinfo: dt: Feb2024 vid: 148 iid: 2 pid: 2550 pub: College of American Pathologists place: Northfield, Illinois artinfo: ui: 175180329 175180329 175180329 10.5858/arpa.2022-0335-RA 175180329 ppf: 242 ppct: 14 formats: fmt: @attributes: type: P tig: atl: Emerging Landscape of Targeted Therapy of Breast Cancers With Low Human Epidermal Growth Factor Receptor 2 Protein Expression. aug: au: Tozbikian, Gary Krishnamurthy, Savitri Bui, Marilyn M. Feldman, Michael Hicks, David G. Jaffer, Shabnam Khoury, Thaer Shi Wei Wen, Hannah Pohlmann, Paula affil: Department of Pathology, The Ohio State University, Wexner Medical Center, Columbus sug: subj: Breast Neoplasms Drug Therapy Immunohistochemistry Epidermal Growth Factor Receptors Physiology Gene Expression Proteomics Gene Amplification ab: Context.-- Human epidermal growth factor receptor 2 (HER2) status in breast cancer is currently classified as negative or positive for selecting patients for anti-HER2 targeted therapy. The evolution of the HER2 status has included a new HER2-low category defined as an HER2 immunohistochemistry score of 1+ or 2+ without gene amplification. This new category opens the door to a targetable HER2-low breast cancer population for which new treatments may be effective. Objective.-- To review the current literature on the emerging category of breast cancers with low HER2 protein expression, including the clinical, histopathologic, and molecular features, and outline the clinical trials and best practice recommendations for identifying HER2-low-expressing breast cancers by immunohistochemistry. Data sources.-- We conducted a literature review based on peer-reviewed original articles, review articles, regulatory communications, ongoing and past clinical trials identified through ClinicalTrials.gov, and the authors' practice experience. Conclusions.-- The availability of new targeted therapy potentially effective for patients with breast cancers with low HER2 protein expression requires multidisciplinary recognition. In particular, pathologists need to recognize and identify this category to allow the optimal selection of patients for targeted therapy. pubtype: Academic Journal doctype: pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|